The 2022-2024 mpox response exposed stark equity gaps — vaccines and antivirals ...
Africa Trials
1
US Trials
8
Gap Ratio
8x
Nations
54
Key Finding
Africa hosted 1 mpox trials versus 8 in the United States, a 8-fold disparity in research investment.
Regional Comparison
Distribution Analysis
Inequality Profile
Temporal & Structural
Why It Matters
The 2022-2024 mpox response exposed stark equity gaps — vaccines and antivirals flowed to high-income countries while African nations with endemic clade I received minimal trial investment.
The Evidence 134 words · target 156
In the burden-versus-investment landscape of African health research, does the distribution of mpox trials across African nations reveal a systematic research gap? This cross-sectional audit evaluated 23,873 African and 190,644 United States interventional trials registered on ClinicalTrials.gov through April 2026. Investigators computed the Bayesian posterior trial rate as the primary estimand using registry metadata for each nation. Africa hosted 1 mpox trials (0.0% of its portfolio) compared to 8 in the United States, yielding a 0.0-fold disparity in per-population investment. Temporal analysis showed 17.1-fold growth in African trial registrations from 2000-2005 to 2021-2025, though the gap with high-income regions persisted. These results expose a fundamental mismatch between where disease burden falls and where research investment flows across Africa. Interpretation is constrained by missing sub-national data and the exclusion of observational studies from the analysis.
Sentence Structure
Question
In the burden-versus-investment landscape of African health research, does the distribution of mpox trials across African nations reveal a systematic research gap?
Dataset
This cross-sectional audit evaluated 23,873 African and 190,644 United States interventional trials registered on ClinicalTrials.
Method
gov through April 2026.
Primary Result
Investigators computed the Bayesian posterior trial rate as the primary estimand using registry metadata for each nation.
Robustness
Africa hosted 1 mpox trials (0.
Interpretation
0% of its portfolio) compared to 8 in the United States, yielding a 0.
Boundary
0-fold disparity in per-population investment.
Extra
Temporal analysis showed 17.
Extra
1-fold growth in African trial registrations from 2000-2005 to 2021-2025, though the gap with high-income regions persisted.
Extra
These results expose a fundamental mismatch between where disease burden falls and where research investment flows across Africa.
Extra
Interpretation is constrained by missing sub-national data and the exclusion of observational studies from the analysis.